Andrews J - Search Results

1

Faecal calprotectin: current usage and perceived beneficial effects of third-party funding on rates of colonoscopy by Australian gastroenterologists.

Elnawsra O, Fok I, Sparrow M, Gibson P, Andrews J, Connor S. Elnawsra O, et al. Among authors: andrews j. Intern Med J. 2016 May;46(5):590-5. doi: 10.1111/imj.13056. Intern Med J. 2016. PMID: 26946938

2

Value of positive technetium-99m leucocyte scans in predicting intestinal inflammation.

Gibson P, Lichtenstein M, Salehi N, Hebbard G, Andrews J. Gibson P, et al. Among authors: andrews j. Gut. 1991 Dec;32(12):1502-7. doi: 10.1136/gut.32.12.1502. Gut. 1991. PMID: 1773957 Free PMC article.

3

Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?

Andrews JM, Travis SP, Gibson PR, Gasche C. Andrews JM, et al. Aliment Pharmacol Ther. 2009 Mar 1;29(5):459-69. doi: 10.1111/j.1365-2036.2008.03915.x. Epub 2008 Dec 11. Aliment Pharmacol Ther. 2009. PMID: 19077129 Review.

4

Psychogastroenterology: a call for psychological input in Australian gastroenterology clinics.

Mikocka-Walus A, Turnbull D, Andrews JM, Moulding N, Wilson I, Holtmann G. Mikocka-Walus A, et al. Among authors: andrews jm. Intern Med J. 2009 Feb;39(2):127-30. doi: 10.1111/j.1445-5994.2008.01862.x. Intern Med J. 2009. PMID: 19356189 Review.

5

Un-promoted issues in inflammatory bowel disease: opportunities to optimize care.

Andrews JM, Mountifield RE, Van Langenberg DR, Bampton PA, Holtmann GJ. Andrews JM, et al. Intern Med J. 2010 Mar;40(3):173-82. doi: 10.1111/j.1445-5994.2009.02110.x. Epub 2009 Oct 22. Intern Med J. 2010. PMID: 19849744 Review.

6

Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia.

Connell W, Andrews JM, Brown S, Sparrow M. Connell W, et al. Among authors: andrews jm. Intern Med J. 2010 Feb;40(2):139-49. doi: 10.1111/j.1445-5994.2009.02122.x. Intern Med J. 2010. PMID: 20446955

7

Potentially avoidable surgery in inflammatory bowel disease: what proportion of patients come to resection without optimal preoperative therapy? A guidelines-based audit.

Gapasin J, Van Langenberg DR, Holtmann G, Hetzel DJ, Andrews JM. Gapasin J, et al. Among authors: andrews jm. Intern Med J. 2012 May;42(5):e84-8. doi: 10.1111/j.1445-5994.2010.02328.x. Epub 2010 Jul 30. Intern Med J. 2012. PMID: 20681962

8

General practitioners' knowledge of and attitudes to inflammatory bowel disease.

Tan M, Holloway RH, Lange K, Andrews JM. Tan M, et al. Among authors: andrews jm. Intern Med J. 2012 Jul;42(7):801-7. doi: 10.1111/j.1445-5994.2011.02586.x. Intern Med J. 2012. PMID: 21883783

9

Probiotics in luminal gastroenterology: the current state of play.

Andrews JM, Tan M. Andrews JM, et al. Intern Med J. 2012 Dec;42(12):1287-91. doi: 10.1111/imj.12015. Intern Med J. 2012. PMID: 23252997 Review.

10

Transition of care in inflammatory bowel disease: mind the gap! Theory, practice and recommendations for an Australian context.

Bryant RV, Trott MJ, Bennett A, Bampton PA, Moore DJ, Andrews JM. Bryant RV, et al. Among authors: andrews jm. Intern Med J. 2013 Nov;43(11):1171-6. doi: 10.1111/imj.12272. Intern Med J. 2013. PMID: 24237644 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,305 results

Search Page

Filters